Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses
- PMID: 15147033
Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses
Abstract
The goal of therapy in the management of patients with major depressive disorder is to achieve and sustain remission. Extensive data on strategies to achieve remission have been published, and more recently, many of these data have been subject to systematic review and metaanalyses. This review compares data from metaanalyses and more recent trials on some of the therapies that may help to achieve remission. Strategies that have demonstrated improved rates of full remission in the treatment of depression include venlafaxine as initial antidepressant therapy, which has been shown to provide higher rates of remission when compared with serotonin reuptake inhibitors and tricyclic antidepressants. For patients who do not respond to initial medication treatment, treatments such as psychotherapy, exercise, light therapy, alternative medicines, and counselling have demonstrated benefits over placebo and may enhance remission rates when used in combination with antidepressants. Preventing relapse and sustaining the fully remitted state over the long term is also important in the management of depression. Continuing antidepressant therapy has been associated with excellent long-term outcomes for many patients. Randomized controlled clinical trials conducted in the last 5 years provide very good evidence to show that achieving and sustaining the fully remitted state is an attainable goal in the management of patients with depression.
Similar articles
-
Psychological therapies for treatment-resistant depression in adults.Cochrane Database Syst Rev. 2018 May 14;5(5):CD010558. doi: 10.1002/14651858.CD010558.pub2. Cochrane Database Syst Rev. 2018. PMID: 29761488 Free PMC article.
-
Antidepressants for the treatment of depression in people with cancer.Cochrane Database Syst Rev. 2018 Apr 23;4(4):CD011006. doi: 10.1002/14651858.CD011006.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2023 Mar 31;3:CD011006. doi: 10.1002/14651858.CD011006.pub4. PMID: 29683474 Free PMC article. Updated.
-
Omega-3 fatty acids for depression in adults.Cochrane Database Syst Rev. 2021 Nov 24;11(11):CD004692. doi: 10.1002/14651858.CD004692.pub5. Cochrane Database Syst Rev. 2021. PMID: 34817851 Free PMC article.
-
Acupuncture for depression.Cochrane Database Syst Rev. 2018 Mar 4;3(3):CD004046. doi: 10.1002/14651858.CD004046.pub4. Cochrane Database Syst Rev. 2018. PMID: 29502347 Free PMC article.
-
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. Cochrane Database Syst Rev. 2021. PMID: 34510411 Free PMC article.
Cited by
-
Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review.Int J Environ Res Public Health. 2022 Jan 4;19(1):523. doi: 10.3390/ijerph19010523. Int J Environ Res Public Health. 2022. PMID: 35010782 Free PMC article. Review.
-
Genome-wide association studies of placebo and duloxetine response in major depressive disorder.Pharmacogenomics J. 2018 May 22;18(3):406-412. doi: 10.1038/tpj.2017.29. Epub 2017 Jul 11. Pharmacogenomics J. 2018. PMID: 28696415
-
STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!Can J Psychiatry. 2015 Jan;60(1):6-8. doi: 10.1177/070674371506000103. Can J Psychiatry. 2015. PMID: 25886543 Free PMC article. No abstract available.
-
Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome.Evid Based Complement Alternat Med. 2007 Dec;4(4):493-502. doi: 10.1093/ecam/nel114. Evid Based Complement Alternat Med. 2007. PMID: 18227917 Free PMC article.
-
Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?Psychopharmacology (Berl). 2023 Aug;240(8):1789-1804. doi: 10.1007/s00213-023-06410-x. Epub 2023 Jul 3. Psychopharmacology (Berl). 2023. PMID: 37394539 Free PMC article.